Bifogade filer
PDF
Kurs
-3,33%
Likviditet
0,39 MSEK
Kalender
| Tid* | ||
| 2025-07-24 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-04-25 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-01-30 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2024-11-29 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2024-11-28 | - | Årsstämma |
| 2024-10-24 | - | Bokslutskommuniké 2024 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q3 |
| 2024-05-27 | - | Extra Bolagsstämma 2024 |
| 2024-04-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-01-25 | - | Kvartalsrapport 2024-Q1 |
| 2023-12-01 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2023-11-30 | - | Årsstämma |
| 2023-10-26 | - | Bokslutskommuniké 2023 |
| 2023-07-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-04-27 | - | Kvartalsrapport 2023-Q2 |
| 2023-01-26 | - | Kvartalsrapport 2023-Q1 |
| 2022-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2022-11-24 | - | Årsstämma |
| 2022-10-27 | - | Bokslutskommuniké 2022 |
| 2022-07-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q2 |
| 2022-01-27 | - | Kvartalsrapport 2022-Q1 |
| 2021-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2021-11-24 | - | Årsstämma |
| 2021-10-29 | - | Bokslutskommuniké 2021 |
| 2021-07-30 | - | Kvartalsrapport 2021-Q3 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-01-29 | - | Kvartalsrapport 2021-Q1 |
| 2020-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2020-11-24 | - | Årsstämma |
| 2020-10-30 | - | Bokslutskommuniké 2020 |
| 2020-07-31 | - | Kvartalsrapport 2020-Q3 |
| 2020-06-03 | - | Extra Bolagsstämma 2020 |
| 2020-04-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-01-31 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-06 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2019-12-05 | - | Årsstämma |
| 2019-10-31 | - | Bokslutskommuniké 2019 |
| 2019-07-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-04-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-01-31 | - | Kvartalsrapport 2019-Q1 |
| 2018-12-05 | - | Årsstämma |
| 2018-11-01 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2018-10-31 | - | Bokslutskommuniké 2017 |
| 2018-07-31 | - | Kvartalsrapport 2017-Q3 |
| 2017-12-06 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2017-12-05 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NextCell Pharma AB* announces that its subsidiary, QVance AB, has published an article in collaboration with the International Society of Cell and Gene Therapy (ISCT). The article, authored by Dr. Lindsay Davies, CSO at NextCell and co-founder of QVance, was published in Cytotherapy and is based on a global survey examining knowledge on particulates in cell and gene therapy (CGT) products.
QVance, founded by cell therapy developers to support other cell therapy developers, aims to become the leading quality analysis company for CGT in the Nordic region. With NextCell's expertise as a foundation, QVance provides quality control tailored to the industry's specific demands, supporting the development of safe therapies.
Dr. Davies comments:
"It is essential that we, together with regulators and industry, establish unified guidelines for CGT. QVance builds on our solid experience in cell therapy to provide other developers with high-quality, practical solutions."
* NextCell Pharma AB, "NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma (https://www.linkedin.com/company/15255207/)
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se (info@nextcellpharma.com)
Website:www.cellaviva.se (http://www.nextcellpharma.com)
Facebook: https://www.facebook.com/cellavivasverige (https://www.linkedin.com/company/15255207/)
Instagram: https://www,instagram.com/cellaviva (https://twitter.com/NextCellPharma)